Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

43 results about "Vancomycin resistant" patented technology

A vancomycin resistant staphylococcus aureus (VRSA) infection is caused by bacteria. These bacteria are resistant to the antibiotic medicine vancomycin. The infection can spread easily from person to person.

Methods And Compositions Including Diagnostic Kits For The Detection of Staphylococcus Aureus

Methods and compositions, including diagnostic kits, for the detection of Staphylococcus Aureus (SA) and clinically important antibiotic resistant forms thereof, such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Staphylococcus aureus (VRSA), mupirocin-resistant Staphylococcus aureus (mupSA), and the like, from individuals in a sample population are disclosed Also disclosed are cost effective methods and kits for bacterial sampling and analysis via inherent and expeditious SA cell disruption methods followed by Direct PCR, circumventing the need, expense and contamination πsks associated with DNA isolation methods These improved methods in conjunction with SA prevalence analysis are applied so as to eliminate the approximately 70% of samples in the human population which do not carry SA (SA negative), followed by a second more costly test for antibiotic resistant forms thereof, such as amplification to confirm for presence of MRSA or other target disease
Owner:OHARA SHAWN MARK +1

Method for detecting the presence or absence of pathogenic Staphylococci in a test sample, including test mixture with micro particles

A presence / absence test for Staphylococcus aureus (S. aureus) involves placing a first generation test sample in a solution that will clot in the presence of S. aureus. The solution contains components that will selectively grow S. aureus and also contains clotting factors that will react with S. aureus, if S. aureus is present in the sample, to clot the solution. Examples of specimen samples that can be tested include nasal swabs and lesion swabs, among others. The test can also be modified to detect the presence or absence of methicillin resistant S. Aureus (MRSA). The addition of micro particles having a size in the range of about 0.1 micron to about 1.0 mm provides localities where the bacteria agglomerate, thereby significantly decreasing the clotting time, and providing a significantly stronger clot. The micro particles can be used in other bacteria tests to accelerate the production of an end result. Such other tests can include a vancomycin-resistant enterococcus test; a Group B Streptococcus test; a test for hemolytic E. coli; and a test for Listeria monocytogenes, to name a few. These tests are all performed in a liquid broth-type reagent mixture and do not necessarily involve clotting of the broth.
Owner:PILOTS POINT LLC

Method and reagents for detecting the presence or absence of staphylococcus aureus in a test sample

A presence/absence test for Staphylococcus aureus (S. aureus) involves placing a first generation test sample in a solution that will clot in the presence of S. aureus. The solution contains components that will selectively grow S. aureus and also contains clotting factors that will react with S. aureus, if S. aureus is present in the sample, to clot the solution. Examples of specimen samples that can be tested include nasal swabs and lesion swabs, among others. The test can also be modified to detect the presence or absence of methicillin resistant S. Aureus (MRSA). The addition of micro particles having a size in the range of about 0.1 micron to about 1.0 mm provides localities where the bacteria agglomerate, thereby significantly decreasing the clotting time, and providing a significantly stronger clot. The micro particles can be used in other bacteria tests to accelerate the production of an end result. Such other tests can include a vancomycin-resistant enterococcus test; a Group B Streptococcus test; a test for hemolytic E. coli; and a test for Listeria monocytogenes, to name a few. These tests are all performed in a liquid broth-type reagent mixture and do not necessarily involve clotting of the broth.
Owner:PILOTS POINT LLC

Vancomycin derivatives and preparation and application thereof

The invention discloses a series of vancomycin derivatives as shown in a formula (I). The series of compounds can be used for treating infection of gram-positive bacteria or vancomycin-resistant bacteria and can be prepared from vancomycin through a chemical synthesis method. (Please see the description for the formula (I).).
Owner:ACESYS PHARMATECH LTD

Compositions and methods for mitigating drug resistant bacteria

The current invention is a broad-based remediation mechanism against MRFs and includes nanotechnology formulations and methodologies that may be used to develop novel mitigation strategies against certain drug resistant bacterial strains. In an embodiment, the current invention relates to mitigation of drug resistant bacteria from nosocomial infections, for example in hospitals and in food animals. The invention uses hybrid nanomaterials comprising oligo-chitosan and zinc oxide formulated as nanoparticles and micelles. The inventors unexpectedly found unique properties of very small oligomers of chitosan that effectively mitigate MRFs- and Vancomycin-Resistant Enterococcus (VRE)-induced illnesses without compromising the balance of the beneficial flora in the abdomen. Also, the combination of chitosan with zinc oxide demonstrated synergistic and unexpected effects in remediation of important food-borne bacteria including the resistant types.
Owner:UNIV OF SOUTH FLORIDA

Pharmaceutical composition as well as preparation method and application thereof

The invention discloses a pharmaceutical composition and application thereof. The pharmaceutical composition is a compound shown as a chemical formula (I) or pharmaceutically acceptable salts and pharmaceutically acceptable carriers thereof: (the formula is shown in the description). The compound can be used for preparing an antibacterial drug, in particular preparing a medicine for preventing or treating vancomycin-resistant bacteria infectious diseases. Experimental data show that the compound is combined with glycopeptide antibacterial drugs, so that the growth of vancomycin-resistant enterococci can be effectively inhibited.
Owner:XIANGTAN ZHILIAN TECH MATASTASIS PROMOTE CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products